Literature DB >> 15596411

Distinct but overlapping T helper epitopes in the 37-58 region of SSX-2.

Maha Ayyoub1, Andrea Merlo, Charles S Hesdorffer, Daniel Speiser, Donata Rimoldi, Jean-Charles Cerottini, Gerd Ritter, Yao-Tseng Chen, Lloyd J Old, Stefan Stevanovic, Danila Valmori.   

Abstract

Because of their specific expression in tumors of different histological types, the products of the SSX genes are important candidate targets for development of cancer vaccines. We have previously identified two immunodominant SSX-2-derived T cell epitopes recognized by HLA-A2-restricted CD8+ T cells (SSX-2 41-49) and HLA-DR11-restricted CD4+ T cells (SSX-2 45-59), respectively. In this study, we report the identification of an HLA-DR3-restricted epitope mapping to the 37-51 region of SSX-2, overlapping both previously identified epitopes. As about one fifth of individuals from several major ethnic groups express HLA-DR3, the identification of this epitope significantly increases the percent of patients that are expected to mount specific CD4+ T cell responses following vaccination with peptides in this region of SSX-2. Retrieval of multiple overlapping epitopes in a defined region of SSX-2 protein suggests the presence of a "hot spot" for T cell recognition that may prove sufficient for the induction of immune responses.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15596411     DOI: 10.1016/j.clim.2004.08.014

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  8 in total

1.  Epigenetic modulation to enable antigen-specific T-cell therapy of colorectal cancer.

Authors:  Jeffrey Chou; Lilien N Voong; Christie L Mortales; Andrea M H Towlerton; Seth M Pollack; Xiaoji Chen; Cassian Yee; Paul F Robbins; Edus H Warren
Journal:  J Immunother       Date:  2012 Feb-Mar       Impact factor: 4.456

2.  Identification of an HLA-DPB1*0501 restricted Melan-A/MART-1 epitope recognized by CD4+ T lymphocytes: prevalence for immunotherapy in Asian populations.

Authors:  Zhaoting Meng; Yadong Wang; Guanzhong Zhang; Yuehua Ke; Yanfeng Yan; Liangliang Wu; Qianrong Huang; Gang Zeng; Yu Wang; Han Ying; Shunchang Jiao
Journal:  J Immunother       Date:  2011-09       Impact factor: 4.456

3.  Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma.

Authors:  Ulrike Gerdemann; Usha Katari; Anne S Christin; Conrad R Cruz; Tamara Tripic; Alexandra Rousseau; Stephen M Gottschalk; Barbara Savoldo; Juan F Vera; Helen E Heslop; Malcolm K Brenner; Catherine M Bollard; Cliona M Rooney; Ann M Leen
Journal:  Mol Ther       Date:  2011-09-13       Impact factor: 11.454

4.  Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells.

Authors:  Heath A Smith; Douglas G McNeel
Journal:  J Immunother       Date:  2011-10       Impact factor: 4.456

Review 5.  The SSX family of cancer-testis antigens as target proteins for tumor therapy.

Authors:  Heath A Smith; Douglas G McNeel
Journal:  Clin Dev Immunol       Date:  2010-10-11

6.  Preexisting CD4+ T-cell immunity in human population to avian influenza H7N9 virus: whole proteome-wide immunoinformatics analyses.

Authors:  Venkata R Duvvuri; Bhargavi Duvvuri; Christilda Alice; Gillian E Wu; Jonathan B Gubbay; Jianhong Wu
Journal:  PLoS One       Date:  2014-03-07       Impact factor: 3.240

Review 7.  Therapeutic Cancer Vaccines-Antigen Discovery and Adjuvant Delivery Platforms.

Authors:  Neftali Ortega Alarcon; Maddy Jaramillo; Heidi M Mansour; Bo Sun
Journal:  Pharmaceutics       Date:  2022-07-11       Impact factor: 6.525

8.  Development of a novel clustering tool for linear peptide sequences.

Authors:  Sandeep K Dhanda; Kerrie Vaughan; Veronique Schulten; Alba Grifoni; Daniela Weiskopf; John Sidney; Bjoern Peters; Alessandro Sette
Journal:  Immunology       Date:  2018-08-06       Impact factor: 7.397

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.